- Home
- ANIK vs CRDF Comparison
ANIK vs CRDF Comparison
Compare ANIK & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIK | CRDF |
|---|---|---|
| Founded | 1983 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 134.8M | 187.9M |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIK | CRDF |
|---|---|---|
| Price | $9.39 | $2.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $16.00 | $10.83 |
| AVG Volume (30 Days) | 130.0K | ★ 869.1K |
| Earning Date | 03-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $112,806,000.00 | $501,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.55 | N/A |
| 52 Week Low | $7.87 | $1.90 |
| 52 Week High | $18.37 | $4.99 |
Technical Indicators
Market Signals| Indicator | ANIK | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 56.85 |
| Support Level | $9.16 | $2.72 |
| Resistance Level | $9.60 | $3.02 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 23.74 | 47.73 |
Price Performance
Historical ComparisonAbout ANIK Anika Therapeutics Inc.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States and also has its presence in Europe and Other countries.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.